Rupert Bartsch

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos et al. · The Lancet Oncology · 2019 · 477 citations

Medicine, Oncology, Pharmacology +14

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Michael Gnant, Martin Filipits, Richard Greil et al. · Annals of Oncology · 2013 · 399 citations · Full text

Medicine, Oncology, Breast Oncology +13

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Rupert Bartsch, Anna S. Berghoff, Julia Furtner et al. · Nature Medicine · 2022 · 392 citations · Full text

Medicine, Oncology, Pharmacology +17

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases

Anna S. Berghoff, Elisabeth Fuchs, Gerda Ricken et al. · OncoImmunology · 2015 · 310 citations · Full text

Medicine, Immunology, Oncology +17